Literature DB >> 9504701

Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients.

D Bernard1, C Lançon, P Auquier, G Reine, D Addington.   

Abstract

The Calgary Depression Scale for Schizophrenia (CDSS) is a nine-item structured interview scale developed by Addington et al. to assess depression in schizophrenics. This paper describes the testing of the reliability and validity of the French version of the CDSS in a population of 70 schizophrenic patients. The validity of the CDSS as a measure of depression was confirmed; a single factor accounted for 41% of the variance of the nine items. The total score on the CDSS was strongly correlated with those on the Montgomery-Asberg Depression Rating Scale (MADRS), the Hamilton Depression Rating Scale (HDRS) and also the G6 item (depression) of the Positive and Negative Syndrome Scale (PANSS). The correlation with the Psychomotor Retardation Scale (ERD) total score was much less significant and was better with the 'subjective' subscore. The internal consistency was good, with a Cronbach's alpha of 0.79. A high level of inter-rater reliability was observed (weighted kappa values were >0.75 in all cases). The CDSS has a lower stability over time than other depression scales. It is a simple, quick and reliable scale for assessing depression in schizophrenic populations.

Entities:  

Mesh:

Year:  1998        PMID: 9504701     DOI: 10.1111/j.1600-0447.1998.tb09960.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  13 in total

1.  Heavy cannabis use prior psychosis in schizophrenia: clinical, cognitive and neurological evidences for a new endophenotype?

Authors:  Jasmina Mallet; Nicolas Ramoz; Yann Le Strat; Philip Gorwood; Caroline Dubertret
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-02-11       Impact factor: 5.270

2.  Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset.

Authors:  Romain Rey; Thierry D'Amato; Laurent Boyer; Lore Brunel; Bruno Aouizerate; Fabrice Berna; Delphine Capdevielle; Isabelle Chereau; Gabrielle Chesnoy-Servanin; Hélène Denizot; Jean-Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Christophe Lancon; Jasmina Mallet; David Misdrahi; Christine Passerieux; Aurélie Schandrin; Franck Schürhoff; Mathieu Urbach; Pierre Vidailhet; Pierre-Michel Llorca; Guillaume Fond
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-07       Impact factor: 5.270

3.  Thematic analysis of the raters' experiences administering scales to assess depression and suicide in Arab schizophrenia patients.

Authors:  Iman Amro; Suhaila Ghuloum; Samer Hammoudeh; Yahya Hani; Arij Yehya; Hassen Al-Amin
Journal:  BMC Psychiatry       Date:  2022-10-21       Impact factor: 4.144

4.  Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis.

Authors:  Jean Addington; Hely Shah; Lu Liu; Donald Addington
Journal:  Schizophr Res       Date:  2014-01-16       Impact factor: 4.939

5.  Validation of the French Clinical Assessment Interview for Negative Symptoms in a Sample of Stable French Individuals With Schizophrenia.

Authors:  Yasmine Laraki; Cindy Lebrun; Marine Merenciano; Margot Eisenblaetter; Jerôme Attal; Alexandra Macgregor; Amandine Decombe; Delphine Capdevielle; Stéphane Raffard
Journal:  Front Psychiatry       Date:  2022-04-01       Impact factor: 4.157

Review 6.  Augmentation with antidepressants in schizophrenia treatment: benefit or risk.

Authors:  Ye-Meng Mao; Ming-Dao Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-16       Impact factor: 2.570

7.  Validation of the Arabic Version of Calgary Depression Scale for Schizophrenia.

Authors:  Yahya Hani; Suhaila Ghuloum; Ziyad Mahfoud; Mark Opler; Anzalee Khan; Arij Yehya; Abdulmoneim Abdulhakam; Samer Hammoudeh; Azza Al-Mujalli; Reem Elsherbiny; Hassen Al-Amin
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

8.  Possible Facilitative Effects of Repeated Anodal Transcranial Direct Current Stimulation on Functional Outcome 1 Month Later in Schizophrenia: An Open Trial.

Authors:  Zui Narita; Takuma Inagawa; Kazuki Sueyoshi; Crystal Lin; Tomiki Sumiyoshi
Journal:  Front Psychiatry       Date:  2017-09-29       Impact factor: 4.157

9.  Depression: An actionable outcome for those at clinical high-risk.

Authors:  Jean Addington; Megan S Farris; Lu Liu; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; William S Stone; Matcheri Keshevan; Scott W Woods
Journal:  Schizophr Res       Date:  2020-10-29       Impact factor: 4.939

10.  Reliability and validity of the Thai version of the Calgary Depression Scale for Schizophrenia.

Authors:  Sirijit Suttajit; Manit Srisurapanont; Sutrak Pilakanta; Chawanun Charnsil; Siritree Suttajit
Journal:  Neuropsychiatr Dis Treat       Date:  2013-01-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.